{"product_id":"eribulin-mesylate-injection-1-mg-2-ml-0-5-mg-ml","title":"Eribulin Mesylate Injection 1 mg\/2 mL (0.5 mg\/mL) Single-Dose Vial 2 mL (RX)","description":"\u003cp\u003e\u003cstrong\u003eEribulin Mesylate Injection 1 mg\/2 mL (0.5 mg\/mL)\u003c\/strong\u003e is an FDA-approved, cutting-edge antineoplastic agent used in the treatment of \u003cstrong\u003emetastatic breast cancer\u003c\/strong\u003e and \u003cstrong\u003eunresectable or metastatic liposarcoma\u003c\/strong\u003e. This single-dose, sterile, 2 mL vial delivers precise dosing and reliable administration in hospital, infusion center, and oncology clinic settings. Eribulin Mesylate is a synthetic analog of halichondrin B, proven to extend survival in patients with advanced or treatment-resistant cancer.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eAdvanced Chemotherapy for Metastatic Breast Cancer \u0026amp; Liposarcoma\u003c\/strong\u003e\u003c\/h3\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003e\u003cstrong\u003eUses:\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eEribulin Mesylate Injection is indicated for:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMetastatic Breast Cancer:\u003c\/strong\u003e In patients who have previously received at least two chemotherapy regimens for late-stage disease, including an anthracycline and a taxane (unless contraindicated).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eUnresectable or Metastatic Liposarcoma:\u003c\/strong\u003e In adults who have received prior anthracycline-containing chemotherapy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eFor Intravenous Infusion Only\u003c\/strong\u003e: Not for intramuscular, subcutaneous, or oral administration. Must be diluted and administered under healthcare professional supervision.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eMechanism of Action\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003eEribulin is a \u003cstrong\u003emicrotubule dynamics inhibitor\u003c\/strong\u003e—it blocks cancer cell growth and division, helping reduce tumor size and slow cancer progression. As a non-taxane microtubule inhibitor, it offers an alternative for patients resistant to conventional chemotherapy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCommon Side Effects:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eNeutropenia (low white cell count)\/leukopenia:\u003c\/strong\u003e Risk of infection\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAnemia, thrombocytopenia:\u003c\/strong\u003e Fatigue or bruising\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePeripheral Neuropathy:\u003c\/strong\u003e Tingling, numbness, or pain in hands and feet\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHair loss (alopecia), constipation, nausea, vomiting\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFatigue, fever, muscle pain (myalgia)\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eSerious Side Effects:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eSevere neutropenia or febrile neutropenia (potentially life-threatening infections)\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eQT interval prolongation and heart rhythm disturbances\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eLiver dysfunction and increased liver enzymes\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSevere allergic\/anaphylactic reactions\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImportant:\u003c\/strong\u003e Regular monitoring of blood cell counts, liver function, and heart (ECG) is required during therapy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eContraindications:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHypersensitivity to Eribulin or components\u003c\/li\u003e\n\u003cli\u003ePregnancy and breastfeeding (Category D: may cause fetal harm)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cstrong\u003eCDC and Chemotherapy Safety Guidelines:\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eAccording to CDC and OSHA guidelines for chemotherapy agents:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEribulin Mesylate Injection must be administered \u003cstrong\u003eonly by trained healthcare providers\u003c\/strong\u003e, in certified facilities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrict adherence to cytotoxic drug handling\u003c\/strong\u003e (PPE, negative pressure rooms, closed-system drug-transfer devices).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDouble-check dosage \u0026amp; patient identity\u003c\/strong\u003e before administration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDispose of used vials and materials as hazardous medical waste\u003c\/strong\u003e in accordance with federal and local regulations.\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePregnant or breastfeeding staff should not prepare or handle eribulin injections.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003eMonitor patients for infusion reactions and cytopenias per protocol.\u003c\/li\u003e\n\u003cli\u003eProvide \u003cstrong\u003epre-treatment and ongoing patient education\u003c\/strong\u003e for symptom and infection reporting.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eAlways consult institutional protocols and CDC Safe Handling of Hazardous Drugs for full safety guidance.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eWhy Choose Eribulin Mesylate Injection?\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinically proven\u003c\/strong\u003e to prolong overall survival in advanced cancer\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eUniform dosing:\u003c\/strong\u003e 1 mg\/2 mL single-dose vial simplifies preparation\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSterile, ready-to-use packaging\u003c\/strong\u003e for oncology pharmacy safety\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eOptimized for hospital, infusion center, and oncology clinic protocols\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSupported by NCCN, ASCO, ESMO, and CDC guidelines\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cstrong\u003eEribulin Mesylate Injection 1 mg\/2 mL (0.5 mg\/mL): Advanced, Targeted Cancer Care\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOrder today\u003c\/strong\u003e for hospital and oncology pharmacy use—empower your fight against advanced breast cancer and liposarcoma with the most trusted, safety-optimized injectable chemotherapy!\u003c\/p\u003e","brand":"Hikma Injectables","offers":[{"title":"Default Title","offer_id":52657741922672,"sku":"00143-9167-01","price":775.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Eribulin-Mesylate-Injection-1-mg_2-mL-Hikma.jpg?v=1762262191","url":"https:\/\/www.mountainside-medical.com\/products\/eribulin-mesylate-injection-1-mg-2-ml-0-5-mg-ml","provider":"Mountainside Medical","version":"1.0","type":"link"}